 
 
 
 
A PHASE 3 RANDOMIZED STUDY TO 
CONFIRM THE EFFICACY OF AN INTRA - 
ARTICULAR INJECTION OF AMPI[INVESTIGATOR_45372]™ IN 
ADULTS WITH PAIN DUE TO SEVERE 
OSTEOARTHRITIS OF THE KNEE  
 
STUDY NUMBER: AP -003-C 
 
NCT 031 [ZIP_CODE]  
 
9 November 2017  
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
1 
  
 
 
CLINICAL STUDY PROTOCOL  
 
A PHASE 3 RANDOMIZED STUDY TO CONFIRM THE 
EFFICACY OF AN INTRA-  ARTICULAR INJECTION OF 
AMPI[INVESTIGATOR_45372]™  IN ADULTS WITH  PAIN D UE TO SEVERE 
OSTEOARTHRITIS OF THE KNEE  
 
 
 
STUDY NUMBER: AP-003-C 
 
 
Drug Development P hase: Phase [ADDRESS_296194]:  Ampi[INVESTIGATOR_2394]™  
Indication:  Severe Osteoarthriti s of the knee 
Sponsor:  Ampio Phar maceuticals,  Inc. 
[ADDRESS_296195]  
Englewood, CO [ZIP_CODE]  
Date:  Version 1. [ADDRESS_296196] : In accordance with the ethical principles that originate from the Declaration of 
He
lsinki and that are consistent with International Conference on Harmonisation (ICH) 
g
uidelines on Good Clinical Pract ice (GCP) an d regulatory requirements as applicable. 
 
 
 
 
 
 
Con
fidential Information  
This docume
nt is the sole property of Ampio Pharmaceuticals, Inc.  This document and 
a
ny and all information contained herein has to be considered and treated as strictly 
confidential.  This document shall be used only for the purpose of the disclosure herein 
provide
d.  No disclosure or publication shall be made without the prior written consent of 
A
mpio Pharmaceuticals, Inc. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
[ADDRESS_296197]
udy No . AP-003-C version 1.3  dated 09 November 2017, and agree to meet al l 
obligations as detailed in all applicable regulations and guidelines. 
 
 
 
 
 
  
Signed by:  
 
 
 
 
 
 
 
 
 
<Study personnel signature> <Enter date>  
 
 
 
 
 
 
 
 
 
 
 
<Printed name>  
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
3 
  
PROTOCOL SYNOPSIS  
 
Sponsor:  
 
Ampio Phar maceuticals,  Inc. Investig ational Product:  
 
Ampi[INVESTIGATOR_2394]™  Developmental Phase:  
 
Phase 3  
Title of Study:  
 
A Phase 3 Randomized Study to Confirm  the Efficacy of an Intra -Artic ular Injection of 
Ampi[INVESTIGATOR_243760]:  
 
AP-003-C 
Study Center(s):  
 
Approxi mately 1 4 sites 
Indication:  
 
Severe  osteoarthritis ( OA) of the knee (Kellgren Lawrence Grade 4)  
Numbe r of subjects:  
 
[ADDRESS_296198] s total 
Objective s: 
 
The primary trial objective is to evaluate  the efficacy of a  single 4 mL Ampio n™ intra -
articular injection . 
 The seco ndary trial objective is to evaluate  the safety of an intra -articular injection of Ampi[INVESTIGATOR_243761]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
4 
  
Sponsor:  
 
Ampio Phar maceuticals,  Inc. Investig ational Product:  
 
Ampi[INVESTIGATOR_2394]™  Developmental Phase:  
 
Phase 3  
Methods:  
 
The study will have a 7-day screening period for each patient followed by  a 12-week participation 
period. A total of  171 subjects with knee pain  and decreased function  due to severe osteoarthritis 
of the knee (KL IV) will be enrolled.  In order to reduce the potential for bias in reporting 
outcome s, subjects wil l be randomized 6:1 (Ampi[INVESTIGATOR_243762]-articular injection or saline intra -
articular injection).  Study visits will include: Screening visit, Baseline, a [ADDRESS_296199] s of Ampio n treatment on OA pain , function and PGA  will be ev aluated during 
in-clinic visits at 6 and 12 weeks, and telephone contacts at 2 and 10 weeks, u sing the Western 
Ontario and McMaster  Universities Arthritis Index (WOMAC®), and the Patient’s Global 
Assess ment of disease severity (PGA).  
 
The WOMAC® is a validated osteoarthritis scoring syst em and sets the standar d for the 
subject response . In order not to bias the collection of data, only questions from  the 
validated WOMAC scale and PGA will be asked of  subjects.  
 
Clinical be nefit will be established by [CONTACT_243810] -OARSI using the WOMAC  5-
point Likert scale and PGA as assessments durin g the in-office visits and phone visits. Sa fety will 
be asses sed by [CONTACT_243811] (po st-injection and at all follow up contacts), physical 
examination and vitals ( Baseline, Weeks 6 and 12), and laboratory tests (Screening and Week 12).  
Diagnosis and Main Criteria for Inclusion:  
 
1. Able to provid e writte n informed consent to participate in the  study;  
2. Willing and able to  comply with all  study req uirements and ins truction s of the site study 
staff; 
3. Male or fe male, 40 years to 85 years old (inclusive);  
4. Must be a mbulatory;  
5. Study knee must have a  clinical diagnosis of OA supported by [CONTACT_137894] 
(Kellgren Lawrence G rade 4) which is assessed locally (x -rays within the past 6 months 
of screening are acceptable);  
6. Moderate to moderately -severe  OA pain in the study knee (rating  of at least 1.5 on the 
WOMAC A, 5 -point Likert pain subscale);  
7. Moderate to moderately -severe  OA function in the study knee (rating  of at least 1.5 on 
the WOMAC C, 5 -point Likert Function subscale);  
8. WOMAC A, 5 -point Likert pain sub scale <1.5 in the contralateral  knee;  
9. Ability  to discontin ue NSAID use at Screening visit and/or 72 hours prior to the 
Baseline visit and for the dura tion of the clinical study (low -dose Aspi[INVESTIGATOR_248] (81 mg) is 
allowed during the study);  
10. No analgesia (including  aceta minophen) ta ken 24  hours pri or to an efficacy measure;  
11. No known clinically significant  liver abnor mality (e.g. cirrho sis, transplant, etc.).  
 
Main Criteri a for Exclusion:  
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
5 
  
Sponsor:  
 
Ampio Phar maceuticals,  Inc. Investig ational Product:  
 
Ampi[INVESTIGATOR_2394]™  Developmental Phase:  
 
Phase [ADDRESS_296200] unfit for the study  
2. A history of allergic reactions to human albu min (reaction to non-human albu min such as 
egg albu min is not an e xclusion criterion)  
3. A history of allergic reactions to excipi[INVESTIGATOR_190845] 5% hu man albu min (N -acetyltryptophan, 
sodium  caprylate)  
4. Presence of  tense effusi ons 
5. Inflam matory or crystal arthro pathies, acute fractures, history  of aseptic necrosis or joint 
replace ment in the affected kn ee, as assessed locally by [CONTACT_941] P rincip al Investigator 
6. Isolated patella fe moral syndro me, also known as chondro malacia  
7. Any other disease or  condition  interfer ing with t he free use a nd evaluatio n of the study 
knee for the duration of the trial (e.g. cancer, congenital de fects, spi[INVESTIGATOR_243763])  
8. Major injury to the study knee within the  12 months prior to sc reening  
9. Severe hip osteoarthritis i psilateral to the  study knee  
10. Any pain that could interfere  with the assess ment of study knee  pain (e.g. pain in any 
other part of  the lower  extremities, pain ra diating  to the kne e) 
11. Any phar macological or non -pharmacological treat ment targeting  OA starte d or changed 
during the 4 weeks prior to r andomization or likely to be chang ed durin g the duratio n of 
the study  
12. Pregnancy or planning to bec ome pregnant during the study.  
13. Use of the following medications:  
a. No IA injected medications in the study knee during the study. No Hylau ronic Acid 
(HA) injections in the study knee at least [ADDRESS_296201] 4 weeks prior to Baseline.  
b. No analgesics containing opi[INVESTIGATOR_2438].  
c. NSAIDs are not per mitted during t he study; aceta minophen is available as a resc ue 
medication during the study from the provided supply.  
d. No topi[INVESTIGATOR_243764] g the study 
e. No significant anticoagulant therapy (e.g. Heparin or Lovenox)  during the study 
(treat ment such as low -dose As pi[INVESTIGATOR_248] (81 mg) and Plavix are all owed)  
f. No syste mic treat ments that may interfere with safety or effic acy assessments during 
the study  
g. No immunosuppressants  
h. No use of syste mic or intra -articular corticosteroids  
14. No hu man albumin treat ment in the [ADDRESS_296202], Dose and Mode of Administration:  
 
Ampi[INVESTIGATOR_2394], 4 mL, single intra -articular injection in the knee  
  Reference Therapy, Dose and Mode of Administration:  
Saline 4  mL; single intra -articular injection in the knee   
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
6 
  
Sponsor:  
 
Ampio Phar maceuticals,  Inc. Investig ational Product:  
 
Ampi[INVESTIGATOR_2394]™  Developmental Phase:  
 
Phase 3  
Stud y Duration: 
 
12 weeks  
Criteria for Evaluation:  
 
Efficacy:  
WOMA C Osteoarthriti s Index 3.1, 5-point Liker t scale Patie nt 
Global Assess ment 
 
Safety: 
Safety will be assessed by [CONTACT_243812] (post -injection and at all follow -up 
contacts), change in laboratory analysis ( Screening  to Week 12), physical examination and 
vitals (Baseline, Weeks 6 and 12).  
 
Clinical Endpoints:  
Primary Efficacy Endpoint:  
- Evaluate improvement of OMERACT -OARSI response of a single 4 mL Ampi[INVESTIGATOR_243765] -
articular injection  from Baseline  to Week 12  
Secondary Efficacy Endpoints:  
- Evaluate improvement in  the composite endpoint of pain and function (WOMAC A and 
C) from Baseline to  Week 12  
- Evaluate i mprovement in PGA from Baseline to Week 12  
- Evaluate improvement in the composite endpoint of pain and function (WOMAC A and 
C), compared to saline from all single -injection Ampi[INVESTIGATOR_243766]:   
For the primary endpoint evaluating th e proportion of patients who are OMERACT -OARSI 
responders , the following hypothesis will be tested.  
 
 H0:π ≤ π0 versus H A:π > π0      
 
 Where π 0 is the hypothesized value for the proportion of responders.  The value will be 30% 
in this study.   This test will be tested using an exact binomial test.   That is, given the sample 
size of n, the number of responders X, and the value of π0 =0.30, then probability that X or 
more events would be observed will be calculated as the p -value.  Since this is a one -sided 
test, the alpha level will be 0.025.  
 
Blinding and Randomization  
 
Subjects will be assigned in a 6:1 ratio  to treatment by a randomization schedule developed 
and maintained by [CONTACT_243813]. Ampi[INVESTIGATOR_243767]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
[ADDRESS_296203] of the 
study will remain blinded to treatment.  
A comprehensive presentation of  the data management and statistical analysis plan will be 
approved by [CONTACT_243814], Inc. prior to unblinding of study data.  
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
[ADDRESS_296204] OF ABBREVIATIONS AN D  DEFINITION OF TERMS  ................................ ..........  12 
1
 INTRODUCTION ..........................................................................................................  14 
1.1 S tudy Drug  ...........................................................................................................  14 
1.2 B ackground to the Disease.  ..................................................................................  15 
1.3 P revious Human Experience  ................................................................................  17 
1.4 P reclinical Data  ....................................................................................................  17 
1.4.1 P harmacology Studies  ................................ ................................................  17 
1.4.2 Tox icity and Safety Studies  ....................................................................... 18  
1.5 C linical Experience  ..............................................................................................  18 
2
 RATIONALE FOR THE STUDY ..................................................................................  23 
2.1 R ationale for the Doses and the Dosing Regimen  ................................................ 23  
3 STUDY DESIGN. ...........................................................................................................  24 
3.1 S tudy Design Overview  .......................................................................................  24 
3.2 S TUDY OBJECTIVES  ........................................................................................  24 
3.2.1 P ri mary Objective  ......................................................................................  24 
3.2.2 S econdary Objective  ..................................................................................  24 
3.3 S afety Monitoring committee  ..............................................................................  24 
3.4 S toppi[INVESTIGATOR_1869]  .....................................................................................................  25 
3.5 S tudy Endpoints  ................................................................................................ ... 25  
3.5.1 P ri mary Endpoint  .......................................................................................  25 
3.5.2 S econdary Endpoint  ...................................................................................  25 
3.5.3 Ex ploratory Endpoint  ................................ .................................................  25 
3.6 B linding and Randomization  ...............................................................................  25 
4
 SELECTION OF SUBJECTS. ................................ ........................................................  26 
4.1 Num ber of Subjects.  .............................................................................................  26 
4.2 R ecruitment Methods  ...........................................................................................  26 
4.3 I nclusion Criteria  ................................ ................................................................ .. 26 
4.4 Ex clusion Criteria  ................................................................................................  27 
4.5 I nclusion of Subjects Incapable of Giving Informed Consent  .............................  27 
5 S TUDY PLAN AN D PROCEDURES  ..........................................................................  28 
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
9 
 5.1 De scription of Study visits  ................................ ...................................................  28 
5.1.1 Visi t 1 (Day -7 through Day 0, in-clinic); Screening.  ................................  28 
5.1.2 Visi t 2 (Day 0, in-clinic) Baseline/Randomization/Treatment  ..................  29 
5.1.3 Visi t 3 (Day 1, telephone contact)  .............................................................  29 
5.1.4 Visi t 4 (Week 2 ± [ADDRESS_296205])  ............................................  29 
5.1.5 Visi t 5  (Week 6 ± 7 days, in-clinic)  ...........................................................  30 
5.1.6 Visi t 6 (Week 10 ± [ADDRESS_296206])  ................................ ..........  30 
5.1.7 Visi t 7  (Week 12 ± 7 days, in-clinic)  .........................................................  30 
5.1.8 Ea rly Termination Visit  ................................................................ .............  31 
5.1.9 Unsc heduled Visits  ....................................................................................  31 
5.1.10 Mis sed Visits  ..............................................................................................  31 
5.1.11 C ONCOMITAN T MEDICATIONS AND RESCUE MEDICATION  .......32 
6 METH ODS OF ASSESSMENT  ....................................................................................  33 
6.1 Ef ficacy Assessments  ...........................................................................................  34 
6.1.1 W OMAC® Osteoarthritis Index (Bellamy 1988)  ...................................... 34  
6.1.2 P atient’s Global Assessment of Disease Severity (PGA)  ..........................  [ADDRESS_296207] ug Storage and Accountability  ................................ ......................................... 38 
8.3 Tr eatment Complianc e  .........................................................................................  39 
9 ADV ERSE EVENT S  ..................................................................................................... 40  
9.1 De finition  of an adverse event  ................................ ..............................................  40 
9.2 De finition  of a Serious Adverse Event  ................................ ................................ . 40 
9.3 R ecording of adverse events and serious adverse events  ..................................... 41 
9.3.1 AE  Follow up  .............................................................................................  41 
9.3.2 Ove rdose  .................................................................................................... 42  
9.4 S erious Adverse Event Reporting  ................................ ........................................ 42 
9.4.1 R eporting Requirements  ................................................................ ............  42 
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
10 
 9.4.2 SAE  Information  ........................................................................................  42 
10
 STATISTICAL METHODS  ..........................................................................................  43 
10.1 GE NERAL CONSIDERATIONS  ................................ ........................................ 43 
10.1.1 S tatistical and Analytical Plan:  ................................................................ .. 43 
10.2 S TATISTICAL OBJECTIVES  ................................................................ ............  43 
10.3 ANA L YSIS POPUL ATIONS   ................................................................ ..............  44 
10.3.1 S afety Analysis Population:  ....................................................................... 44  
10.3.2 I ntent- to-treat Population:  ................................................................ ..........  44 
10.3.3 P er Protocol Population:  ................................................................ ............  44 
10.3.4 H ypotheses Tested  .....................................................................................  44 
10.3.5 Ex ploratory Endpoints  ................................ ............................................... 46 
10.3.6 De finition of Study Visits  ................................................................ ..........  46 
10.3.7 Num ber of subjects to receive study drug  ................................ ..................  46 
10.3.8 Dis position  of subjects  ...............................................................................  47 
10.3.9 I nterim analysis  ..........................................................................................  47 
10.3.10 B linding and randomization  ....................................................................... 47  
10.3.11 Da ta presentation   ........................................................................................  47 
[IP_ADDRESS]  D
emographic and Baseline Characteristics:  .................................... 47 
[IP_ADDRESS]  Me
dical History and Physical Examination:  .................................... 47 
[IP_ADDRESS]  C
oncomitant Medications or Treatments:  ........................................ 47 
[IP_ADDRESS]  S
afety data:  ....................................................................................... 48 
10.4 Mis sing Data  ........................................................................................................ 48  
11 REGULATORY, ETHI CAL  AND LEGAL OBLIGATIONS  ................................ ...... 49 
11.1 De claration of Helsinki  ........................................................................................  49 
11.2 Goo d Clinical Practice  .........................................................................................  49 
11.3 I nstitutional Review Boards/Ethics Committees  .................................................  [ADDRESS_296208] Confidentiality and Disclosure ................................................................  49 
11.7 C ollection, Monitoring and Auditing Study Documentation, and Da ta 
Storage  ................................................................................................................. 50 
11.7.1 C ollection of Data and Monitoring Procedures  ......................................... 50 
11.7.2 Auditi ng Procedure  ....................................................................................  51 
11.7.3 R etention of  Documents ................................ .............................................  51 
11.8 Disc losure of Information  ....................................................................................  51 
11.9 Disc ontinuation of the Study  ................................ ...............................................  51 
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
[ADDRESS_296209]-OARSI Criteria………………………………………………….21  
Table 1.5.4 Summary of Treatment-Emergent Adverse Events ........................................ 21 
Ta
ble 6.1 Schedule of Assessments and Procedures .......................................................  36 
Ta
ble 9.1 Definitions of AE Severity. ................................ .............................................  40 
Ta
ble 9.2 Guidelines for Determining the Relationship (i f  any) Between Ad ve rse 
Event and the Study Drug ...............................................................................  [ADDRESS_296210]
 OF IN-TEXT FIGURES  
 
 
Figure 1 LS Mean Change for Ampi[INVESTIGATOR_2394]-Treated Patients Over Time and by 
[CONTACT_26769]………………………………………………………………………….20  
 
Figure 2 Kellgren Lawrence Grading System………………………………………….34 
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
[ADDRESS_296211] OF ABBREVIATIONS AND DEFINITI ON OF TERMS  
 
Abbreviati on Definition  
C degrees  Celsius 
F degrees  Fahrenheit  
g Microgram  
ACR  American College of Rheumatology  
AE adverse  event  
ALP  alkaline  phosphatase  
ALT  alanine  transaminase  (SGPT)  
ARDS  adult  respi[INVESTIGATOR_243768]  (SGOT) 
BP Blood  pressure  
CFR  Code  of Federal  Regulations  
CI confidence  interval  
Cm Centimeter 
CRF case report form 
CRO  Clinical  Research  Organization  
Da Dalton  
DA-DKP  Asp-Ala diketopi[INVESTIGATOR_243769]  
G 11.26 x (RPM/1000 )2 x Radius  (cm) 
GCP  Good  Clinical  Practice  
GGT  gamma -gluta myl transferase  
GI Gastrointest inal 
HSA  human serum albumin 
HCG  Human chorionic gonadotropin  
IA intra-articular  
ICF infor med consent form  
ICH International  Conference  on Harmonisation  
IEC Independent  Ethics  Committee  
IRB Institutional  Review  Board  
ITT intent -to-treat 
kDa Kilodalton  
KL Kellgren  Lawrence  
LDH  lactic  dehydrogenase  
LK Likert  
MCH  mean  cell hemoglobin  
MCHC  mean  cell hemoglobin  concentration  
MCID  Minimal  Clinically  Important  Difference  
MCV  mean  cell volume  
Mg Milligram  
mL Milliliter  
NA not applicab le 
Ng Nanogram  
NSAID  non-steroidal  anti-inflammatory  drug 
OA Osteoarthritis  
OAK  osteoarthritis  of the knee 
OMERACT -OARSI  outcome measures in rheumatology clinical trials and osteoarthritis research 
society international  PGA  patient ’s global  assessment  of disease  severity  
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
13 
  
Abbreviati on Definition  
PP per protocol  populat ion 
Radius  distance  (in centimete rs) from the center  of rotation  to the bottom of tube in 
the rotor  
Rap-[ADDRESS_296212]  operation  proced ure 
TEAE  treatment -emergent  adverse  event  
TEER  trans  endothelial  electrical  resistance  
VAS  Visual Analog Scale  
WBC  white  blood  cell 
WCC  white  cell count 
WO Washout  
WOMAC  Western  Ontario  and McMas ter Univers ities Arthritis  Index  
Ampi[INVESTIGATOR_2394]™  Version 1. 3    09 November  2017  
Clinical Study Protocol: AP -003-C Confidential             
14 
  
1 INTRODUCTION  
 
HSA has a long history of clinical use as a co lloid replacement therapy, dating back over  
60 years.  Currently, HSA is approved for the  indications of hypovolemia, hypoalbuminemia, 
prevention of central volume depletion after paracentesis du e  to cirrhotic ascites, ovarian 
hyperstimulation, adult respi[INVESTIGATOR_1505] (ARDS), acute nephrosis, hemolytic 
disease of the newborn and burns.  In addition to its effects on oncotic pressure, HSA  has 
pharmacological effects including decreased inflammation ( Qu inlan 2005) , decreased 
va
scular permeability ( Evans 2002) and no adverse effect on cardiac safety ( Vincent JL, 
2004). 
 
Ampi[INVESTIGATOR_2394]™, the < 5 kilodalton (kDa) ultrafiltrate of 5% human serum albumin (HSA), is  
being developed to provide relief for the pain of severe osteoarthritis of the knee. There ar e  
no currently F DA approved drugs for th e indication of pain from  se ve re (KL 4) osteoarthritis 
of the knee for which Ampi[INVESTIGATOR_243770]. Ampi[INVESTIGATOR_33535] a heterogeneous solution that contains 
se
veral known small molecules and unknown components that may act synergistically. The 
indi
vidual contribution(s) of the unknown components to the biologic activity of Ampi[INVESTIGATOR_243771] [ADDRESS_296213] been identified in 
commercial HSA preparations [ Gay, 2010].  
 
B
ar-Or et al found that commercial preparations of HSA are heterogeneous in term s of 
post
translational modifications, including C- and N-terminal truncation, cysteinylation, 
g
lycation and nitrosylation (Bar-Or D, 2005). An important modification is the cleavage of 
the two N-terminal amino acids Aspartate (D) and Alanine (A). This occurs by [CONTACT_243341] a 
naturally occurring dipeptidase (Bar-Or 2013) present in plasma and also bound to or 
a
ssociated with leukocytes and endothelial cells ( Ohnuma 2006 ), and activated during the 
FDA required heat-treatment of commercial preparations of HSA. After cleavage, th e 
dipeptide under
goes cyclisation to form a diketopi[INVESTIGATOR_3746] (aspartylalanyl diketopi[INVESTIGATOR_3746] 
[
DA-DKP]). DA-DKP  is found in the  low molecular weight fraction (< 5000 Da )  of 
commercial lots of HSA at concentrations ranging from approximately [ADDRESS_296214] that it is an active ingredient in the 
pharmacological effects of HSA and of Ampi[INVESTIGATOR_2394]™. Other components, such as N-acetyl 
tryptophan and its metabolites and sodium caprylate present in HSA and Ampi[INVESTIGATOR_2394], act 
s
ynergistically with DA- DKP on numerous molecular pathways involved in infla mm ation, 
nociceptive and neuropathic pain, vascular permeability and the resolution of inflammation 
in 
various cell types including synoviocytes, chondrocytes, PBMC, macrophages, memory T 
c
ells, endothelial cells and mesenchymal stem cells (T ho mas, GW 2016) (Fredrick ED 2016) 
(Bar-Or 2015) ( Shimonkevitz 2008 ) (Bar-Or 2006) (Bar-Or 2005)  
 
1
.1 STUD Y DRUG  
 
Ampi[INVESTIGATOR_2394]™ is the < 5 kDa ultrafiltrate of 5% HSA. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
15 
  
1.2 BACKGROUND TO THE DISEASE  
 
Osteoarthritis (OA) remains a leading contributor to global disability, with both hip and knee 
OA accounting for over 17 million years lived with disability ( Cross 2014). OA is the most 
c
ommon form of arthritis and affects up to 38 million adu lts in the US alone. OA is caused 
by [CONTACT_243815] d  bony structures of th e  joint which worsens over tim e 
a
nd leads to progressive thinning of articular cartilage, narr owing of the joint space, synovial 
membrane thickening, osteophyte formation and increased density of subchondral bone. 
The
se changes eventually result in chronic pain and disability and deterioration of the joint 
despi[INVESTIGATOR_243772]. OA of the 
knee is defined in stages as noted by [CONTACT_243816]: Grade 0 (normal knee; no 
osteophytes or joint space narrowing), Grade 1 (possible osteophytic lippi[INVESTIGATOR_243773]), Grade 2 (definite osteophytes an d possible narrowing of joint 
space), Grade 3 (moderate multiple osteophytes, definite narrowing of joint space and some 
sc
lerosis, and possible deformity of the bone ends) and Grade 4 (large osteophytes, marked 
na
rrowing of joint space, severe sclerosis, an d definite deformity of bone ends). 
 
Patients with severe OAK, defined radiologically as KL grade 4, have few treatment options 
for
 pain management. Even with r eported di ff iculties in managing symptoms, including pain, 
a large number of KL [ADDRESS_296215] had to put up with pain until their joint replacement because 
ther
e was nothing else that could be done ( Mc Hugh 2007). The net result is that the patients 
c
ontrol their pain by [CONTACT_243817], and this can progress to the  point of losin g the 
a
bility to ambulate in the community.  There is a consequent loss of the benefits of activity 
a
nd the cond itioning that this provides, leading to a deterioration of health in general, 
including both physical and psychological effects (Cisternas 2016). D ifficult- to-treat pain 
conditions, such as severe OAK, are a challenge for both medical and surgical doctors and 
pa
tients. There is no doubt that patients with chronic pain in general suffer from an unmet 
ne
ed, as FDA agreed stating that there is an unmet medical need among patients with severe 
osteoarthritis . 
 
The
 pain associated with osteoarthritis is now thought to be multifactorial. The pathogenesis of 
pain from OA is comprised of both nociceptive and neuropathic pain pathways resulting from 
severely damaged cartilage, exposed subchondral bone, joint innervation, and less defined 
pathways including the synovium. A recent publication in  January 2016 ( A kinci 2016)  noted 
that the balance between nociceptive and neuropathic pain shifts towards neuropathic pain as 
the severity of the condition increases. The multifactorial nature of the pain of osteoarthritis 
may make pain control more difficult, particularly in patients with severe OA (KL4)  
 
The presence of synovitis in KL 4 patients indicates active ‘inflammatory’ disease process. 
The
se findings were supported with a linear observation of an increasing trend correlated with 
the severity of synovitis related to advancing KL grades. Additionally, KL [ADDRESS_296216] lesions that fluctuate with pain, (i.e., fluctuating bone marrow lesions 
a
nd synovitis) related to a high grade of cartilage loss in KL 4 patients (Guermazi 2015). 
The
se findings were further supported using a unique in vivo imaging technique that detected 
activated and not resting macrophages ( Kraus 2016) . In a patient cohort that included patients 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
16 
  
with severe (KL 4) OAK, the quantity of knee-related activated macrophages was 
statis
tically associated with more severe knee pain and radiographic severity of knee OAK. 
 
The
se data demonstrated that greater macrophage mediated inflammation is a cause of more 
severe pain in KL 4 OAK an d provides a rationale whereby [CONTACT_243818][INVESTIGATOR_2394], demonstrated in vitr o 
with anti- inflammatory and anti-macrophage activity, may mediate sympto m atic relief in this 
patient group. These data further demonstrate the  need  to examine patients by [CONTACT_243819] ( Gue rmazi 2015). 
A
mpi[INVESTIGATOR_243774]-inflammatory activity in vitro against macrophages, monocytes, and 
im
mune cells.  
When the clinical trials of Ampi[INVESTIGATOR_243775], it was assumed that the vehicle for the 
product, saline, would have little to no effect in reducing pain, stiffness, or improving physical 
function.  This control was determined not to be a true placebo, but rather turned out to be 
active treatment.  
The Osteoarthritis Research Society International (OARSI) and Standing Committee for 
Clinical Trials Response Criteria Initiative Outcome Measures in Rheumatology (OMERACT) 
committee, in concert with the international rheumatology community, worked to develop a 
uniform core set of outcome measures for osteoarthritis. While the committee initially 
developed two sets of responder criteria to present the results of changes after treatment in three 
symptomatic domains (pain, function, and patient’s global assessment) as a single variable for 
clinical trials, the committee ultimately worked to create a simplified set of responder criteria, 
Scenario D, which captured the criteria for response.  
In the original plan, for each domain, a response was defined by [CONTACT_17588] a relative and an absolute 
change, with different cut-offs with regard to the drug, the route of administration and the OA 
localization. The formal OMERACT-OARSI scenarios defined a responder as  
a. having achieved a high degree of improvement in pain or a moderate degree of 
improvement in 2 of the 3 response domains (pain, function, global assessment) 
(scenario A) OR  
b. a s having achieved a high degree of improvement in either pain or function, or a 
moderate degree of improvement in 2 of the 3 response domains (scenario B) 
The composite index permits presentation of results of symptom modifying clinical trials in OA 
based on individual patient responses (responder yes/no). The use of composite indices was still 
somewhat controversial in that the original OARSI criteria did not account for multiplicity of 
comparisons, however OMERACT-OARSI worked to rectify this and their conclusions were 
presented at the OMERACT [ADDRESS_296217] and OARSI established a task force aimed at evaluating: (1) the variability of 
observed placebo and active treatment effects using the OARSI responder criteria; and (2) the 
possibility of proposing a simplified set of criteria. Because individual study endpoints in 
studies of NSAIDs in patients with hip or knee osteoarthritis were highly correlated, 
OMERACT-OARSI evaluated six different scenarios to determine whether a simplified set of 
criteria could be developed. The conclusions of the task force were presented and discussed 
during the OMERACT 6 conference, where a simplified set of responder criteria (OMERACT-
OARSI set of criteria) was proposed. Scenario D was chosen by [CONTACT_243820], indicating the 
importance of having both a relative change and an absolute change as part of the criteria for 
response.  
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
17 
 The criteria for a responder using the Likert Scale, where the 20-point change on the VAS scale 
is the same as a 1-point change on the Likert Scale and, similarly, the 10-point change in the 
VAS scale is the same as a 0.5-point change on the Likert Scale, are defined as: 
 
1. Hig h improvement in pain or in function ≥ 50% and absolute change in Likert pain scale 
of ≥[ADDRESS_296218] two of the 3 following: 
a. pain ≥ 20% and absolute change in Likert score ≥0.5 
b. func tion ≥ 20% and absolute change in Likert score ≥0.5 
c. patient’s global assessment ≥ 20% and absolute change in Likert score ≥0.[ADDRESS_296219] of Ampi[INVESTIGATOR_243776]. These studies are summarized in Section 1.5.  
 
1
.4 PRECLIN ICAL DATA  
 
1.4.1 Pharmacology Studies  
 
In vitro pharmacology studies demonstrated that a low molecular weight fraction 
(< 3000 da
ltons [Da]) of more than five commercial preparations of HSA, an d a cyclized 
dipeptide contained in that fraction, Asp- Ala diketopi[INVESTIGATOR_3746] (DA-DKP) have a range of 
a
nti-inflammatory properties, which may be expected to ameliorate the symptoms of 
infla
mmation, including pain, in man ( B ar-Or et al 2006). These studies showed  reduced 
inflammatory cytokine production from human T lymphocytes in vitro vi a  modulation  of 
signal transduction through increased expression of Rap-1, an d inhi bition of macrophage 
activation. In addition, DA -DKP enhanced integrity of human endothelial cell junctions in 
the tr
ansendothelial electrical resistance (TEER) assay, which would result in decreased 
va
scular permeability to the influx of inflammatory cells in vivo. No pharmacokinetics 
studi
es were performed as the pl asma levels of the constituents of the < 5000 Da preparation, 
including
 DA-DKP, after intra- articular injection of a therapeutic dose in man or in 
laboratory animals are anticipated to be below the limits of detection. For more information, 
consult the Investigator Brochure. 
 
 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296220] and safety of 
Ampi[INVESTIGATOR_243777]. Ampi[INVESTIGATOR_243778] 6 clinical studies as a 
sing
le intra articular (IA) injection or as three IA injections ad m inistered every two weeks. [ADDRESS_296221] moderate pain at Baseline (defin ed as a score of at least 
1.5 on th e  WOMAC Index 3.1, 5-point Likert pain subscale at screening) in the study knee, 
whic
h was to have been symptomatic for greater than 6 months with a clinical diagnosis of 
OA confirmed by [CONTACT_137894]. The clinical effects of treatment on OA pain were 
evaluated during clinic visits, wi th phone cal l  follow-ups at intermittent times. 
 
 
T
able 1.5.1 
Su
mmary of the Studies Conducted wi th Ampi[INVESTIGATOR_2394]™  Administered as an Intra Articular Injection to the Knee  
 
Study  Phase  N N, 
KL 2, 3, [ADDRESS_296222]  
Single -Injection  Phase  3 Studies  in Support  of Efficacy  & Safety 
AP-003- 
A 3 329 115 / 139 / [ADDRESS_296223]  
-OARSI  
Rescue  
analgesia  Ampi[INVESTIGATOR_2394],  4 
mL or 
10ml* 
AP-004 3 538 133 / 195/ 
210 Single  IA 
injection  WOMA  
C A 
pain,  5- 
point  
Likert  
scale  Week  12 WOMAC  C 
PGA  
WOMAC  A 
pain over 12 
weeks  Ampi[INVESTIGATOR_2394],  4 
mL 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296224]  
AP-003- 
B 3 480 101 / 247 / 
[ADDRESS_296225] Ampi[INVESTIGATOR_2394],  4 
mL 
Additional  Clinical  Studies  in Support of Safety  
AP-007 1 / 2 47 2 / 23/ 15 Multiple  IA 
injection;  
3 injections,  
every 2 weeks  WOMA  
C A 
pain,  5- 
point  
Likert  
scale  Week  20 WOMAC  B 
WOMAC  C 
PGA  
Physical 
activity  
Radiologic  
changes  Ampi[INVESTIGATOR_2394],  4 
mL 
AP-008 3 342 0 / 114 / 228 Multiple  IA 
injection;  
3 injections,  
every 2 weeks  WOMA  
C A 
pain,  5- 
point  
Likert  
scale  Week  20 WOMAC  B 
WOMAC  C 
PGA  
Physical 
activity  
WOMAC  A 
pain with 
movement  Ampi[INVESTIGATOR_2394],  4 
mL 
AIK 1 / 2 103 33 / 69 / 1 Single  IA 
injection  Pain,  10- 
point  
NRS  Day 3, 8, 
30 and 
84 WOMAC  
total,  parts  
A, B, C 
Range  in 
motion  
Rescue  
analgesia  Ampi[INVESTIGATOR_2394] 10 
ml, alone  or 
in solution  
with 
betamethaso  
ne and/or  
lidocaine  
and/or  
saline  
Total   1839        
*Both doses of Ampi[INVESTIGATOR_2394], [ADDRESS_296226] in the KL 4 patients compared to saline, indicating a reproducible and 
consistent response. Analysis of the combined data demonstrate a statistically significant 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
20 
 
 
result in this underserved patient population. Table 1.5.2 pre sents the data for KL 4 patients  
from all sing le-injection studies, analyzed acco rding to the SAP for the respective stud y. 
 
 
T
able 1.5.2 
D
escriptive Statistics and Analysis Results for KL 4 Subjects for Each Study and All Studies Combined  
 
 
 
 
 
Figure 1 vi sually repr esents th e consistent reduction in pain for Ampio n-treated patients over  
a 12-week period. 
Figure
 1. 
LS Mean Change for Ampi[INVESTIGATOR_2394]-Treated Patients Over Time and by [CONTACT_243821][INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296227]-OARSI criteria  
 
Study ID  Ampi[INVESTIGATOR_243779] (%)  
AP-003-A 59.4%  
AP-003-B 59.7%  
AP-004 57.7%  
Combined  58.6%  
 
 
In addition to the efficacy analysis described in this section, Ampi[INVESTIGATOR_243780] a 
robust safety profile across the three well-controlled, single-injection studies, as well as the 
m
ultiple-injection and early phase trials ( Ta ble 1.5.4). No drug-related Serious Adverse Events 
(SAEs)
 have been reported in 1,839 patients treated during the clinical development program. 
The Adverse Event (AE) profile is similar for Ampi[INVESTIGATOR_243781], with a majority of the AEs 
of 
minor or moderate severity and unrelated to treatment. 
 
T
able 1.5.4 
S
ummary of Treatment-Emergent Adverse Events  
 
 
 
Treatment  emerge nt AE   
 
Saline   
 
Ampi[INVESTIGATOR_243782]   
 
N=907   
 
N=932  
 
 
One or more TEAE   
 
425 (47%)   
 
421 (45%)  
 
 
One or more rel ated TEAE   
 
63 (7%)   
 
73 (8%)  
 
 
KL grade 4   
 
N=338   
 
N=326  
 
 
One or more TEAE   
 
150 (44%)   
 
145 (44%)  
 
 
One or more rel ated TEAE   
 
20 (6%)   
 
24 (7%)  
 
 
 
 
 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296228] severe form of OAK, 
for
 which there is no FDA approved treatment alternative. While opi[INVESTIGATOR_243783] n treat pain, and 
tot
al knee replacement can excise the affected tissues, the ability to treat OAK pain and 
inflammation locally is an unme t medical need.  Currently, when KL 4 patients are treated 
for
 OAK, they are receiving treatment using intra-articular therapy (such as 
viscosupplementation) that were not studied, nor required in th eir  device approvals to 
demonstrate efficacy in the KL 4 population (Rutjes 2012). Without surgery, with only a 
sing
le intra-articular injection of Ampi[INVESTIGATOR_2394], KL 4 patients are able to achieve clin ica lly 
meaningful pain relief. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
23 
  
2 RATIONALE FOR THE STUDY 
 
This is a phase 3 randomized study is to confirm the efficacy of an intra- art icular injection of 
Amp
ion™ and is designed to follow on from the completed single-injection Ampi[INVESTIGATOR_243784]. 
This s
tudy explores the clinical impact of Ampi[INVESTIGATOR_2394]-treatment in patients with severe OA 
using
 criteria developed by [CONTACT_141374]-OARSI ( Pham 2004 ).  
 
The appropriateness of a within-patient multi-component endpoint is generally determined by 
[CONTACT_199752], and as such, the OMERACT-OARSI responder criteria, which evaluates 
pain, function and patient global assessment, and has been deemed clinically meaningful for OA 
trials, remains an endpoint in this clinical investigation. 
 
In addition to evaluating response to treatment (Y/N), the study will evaluate a composite 
endpoint of pain and function, as well as improvement in PGA, using OMERACT-OARSI 
criteria. Analysis of Ampi[INVESTIGATOR_243785]-injection 
Ampi[INVESTIGATOR_2394] s
tudies will also be evaluated.   
 
Ampio plans to evaluate patients who complete study AP-003-C in an open label extension 
st
udy. The protocol for the open-label extension study will be submitted under separate cover.  
 
2.1 RATIONALE FOR THE DOSES AND THE DOSING REGIMEN  
 
This trial will us e  the 4 mL volu m e of Ampi[INVESTIGATOR_243786]-injection studies (AP- 003-A, 
AP-
004, an d  AP - 003 -B). 
Ampi[INVESTIGATOR_2394]™  Version 1. 3       09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296229] 
followe
d by a 12-week participa tion period. A total of 171 subjects with knee pain and 
de
creased function due to severe os teoarthritis (KL 4) will b e e nrolled in a 6:1 randomization 
sc
hema: 4 mL Ampi[INVESTIGATOR_243765]-articular injection: 4 mL saline intra-articular injection.  Study 
visits will include: Screening visit, Baseline, a 24-hour, a post- injection follow-up phone call, 
W
eek 2 phone visit, Week 6, Week 10 phone visit, and Week 12 for a total of 7 visits.  
Screening, Baseline, Week 6 and W eek 12 ar e in-office visits. 
 
The clinical effects of Ampi[INVESTIGATOR_243787]-clinic visits 
a
t 6 and 12 weeks, and telephone contacts at 2 and 10 weeks, using the Western Ontario and 
McMaster Universities Arthritis Index (WOMAC®) and the Patient’s Global Assessment of 
disease severity (PGA). 
 
The WO MAC® is a validated Osteoarthritis scoring system an d sets the  standard for  the 
subj
ect response. In order not to bias the collection of data, only questions from the 
va
lidated WOMAC scale and PGA will be asked of subjects. 
 
Clinical benefit will be established by [CONTACT_243822]-OARSI response using 
the
 WOMAC and PGA scales as assessed during the in-office visits an d phone visits. Safety 
w
ill be assessed by [CONTACT_243812] (post-injection and at all follow-up contacts), 
ph
ysical examinations, vitals (Baseline, Weeks 6 and 12), and laboratory analysis (Screening 
and Week 12). 
 
3.2 STUD Y OBJECTIVES 
 
3.2.1 Primary Objective  
 
The primary trial objective is to evaluate the clinical efficacy of a single intra-articular 
inj
ection (4 mL) of Ampi[INVESTIGATOR_2394]. 
3
.2.2 Secondary Objective  
 
The secondary trial objectives are to evaluate the safety of a single intra-articular injection (4 
mL) of Ampi[INVESTIGATOR_2394]. 
3.3 SAFETY MONITORING COMTTEE  
 
A Safety Monitoring Committee (SMC) will be established to re view the safety of Ampi[INVESTIGATOR_243788]. The SMC will consist of independen t clinicians not involved in the 
clinical trial.  The SMC will be primarily responsible for reviewing any serious Adverse 
Event (SAE) and other clinically important safety findings (e. g., discontinuations due to 
 
AE
s) that may occur during the s tudy.  A charter will be dev eloped to detail the SMC review 
responsibilities, the frequency of meetings, and data evaluation plans. 
 
3
.4 STOPPI[INVESTIGATOR_243789]™  Version 1. 3       09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296230]-OARSI response of a single 4 mL Ampi[INVESTIGATOR_243765]-
articular injection from Baseline to  Week 12 
3
.5.2 Secondary Endpoint  
 
- Evaluate improvement in the composite endpoint of pain and function (WOMAC A and 
C) from Baseline to Week 12  
- Eva
luate improvement in PGA from Baseline to Week 12  
- Eva
luate improvement in the composite endpoint of pain and function (WOMAC A and 
C) compared to saline from all single-injection Ampi[INVESTIGATOR_243784] 
 
3.5.3 Exploratory Endpoint  
 
 N/A  
 
3.6 BLINDING AND RANDOMIZATION  
 
All subjects will be randomized 6:1 to receive Ampi[INVESTIGATOR_2394] 4 mL intra-articular injection or 4 mL 
saline intra-articular injection in the study knee. 
 
A comprehensive presentation of the data management and statistical analysis plan will be 
approved by [CONTACT_243814], Inc. prior to final analysis of study data. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09  November  2017  
Clinical Study Protocol: AP -003-C Confidential    
26 
  
4 SELECTION OF SUBJECTS  
 
4.1 NUMB ER OF SUBJECTS  
 
A total of approximately 171 subjects (146 Ampi[INVESTIGATOR_2394]; 25 Saline) will be enrolled in the study 
to a sing
le (1) intra-articular injection of 4 mL Ampi[INVESTIGATOR_243790] 4 mL saline (6:1). 
 
4.2 RECRUITM ENT METHODS  
 
Subjects will be recruited from the population being seen by [CONTACT_243823].  In addition, notifications about the opportunity fo r  subjects to 
participate in a clinical trial will b e sent to referring physicians.  A description of the clinical 
trial will also be posted at ClinicalTrials.gov, and advertisements and/or other notices may be 
produced to advise potential study subjects on how they may obtain information about study 
participation. All such materials will be reviewed and approved by [CONTACT_243824] w 
Board (IRB) prior to their publication or dissemination. 
 
4.3 INCLUSION CRITERIA  
 
Subjects should fulfill all of the following inclu sion criteria: 
 
1. Able to provide written informed consent to participate in the study; 
2.
 Willing and able to comply with all study requirements and instructions of th e  site study 
staff; 
3. Male or female, 40 years to 85 years old (inclusive); 
4.
 Must be ambulatory; 
5. Study knee must have a clinical diagnosis of OA supported by [CONTACT_137894] 
(K
ellgren Lawrence Grade 4) which is assessed locally (x-rays within the past 6 
months of screening are acceptable); 
6. Moderate to moderately-severe OA pain in the study knee (rating of at least 1.5 on the 
W
OMAC A, 5-point Likert Pain Subscale); 
7.
 Moderate to moderately-severe OA function in the study knee (rating of at least 1.5 
on the WOMAC C, 5-point Likert Function Subscale); 
8.
 WOMAC A, 5-point Likert pain subscale <1.5 in the contralateral knee,; 
9.
 Ability to discontinue NSAID use at Screening visit and/o r 72 hours prior to the 
B
aseline visit and for the duration of the clinical study (low-dose Aspi[INVESTIGATOR_248] (81 mg) is 
a
llowed during the study); 
10. No analgesia (including acetaminophen) taken 24 hours prior to an efficacy measure; 
11. No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.). 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
27 
  
4.4 EXCLUS ION CRITERIA  
 
Subjects fulfilling one or more of the following criteria may not be enrolled in the study: 
 
1. As a  result of medical review and screening investigation, the Principal Investigator 
c
onsiders the subject unfit for the study 
2. A hist ory of allergic reactions to human albumin (reaction to non-human albumin such as 
e
gg albumin is not an exclusion criterion) 
3. A hist ory of allergic reactions to excipi[INVESTIGATOR_190845] 5% human albumin (N-acetyltryptophan, 
sodium caprylate) 
4. P resence of tense effusions 
5. I nflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint 
replacement in the affected knee, as assessed locally by [CONTACT_079] 
6. I solated patella femoral syndrome, also known as chondromalacia 
7. An y other disease or condition interfering with the free use and evaluation of the study 
knee for the duration of the trial (e.g. cancer, congenital defects, spi[INVESTIGATOR_243763]) 
8. Ma jor injury to the study knee within the 12 months prior to screening 
9. S evere hip osteoarthritis ipsilateral to the study knee 
10. Any pain that could interfere with the assessment of study knee pain (e.g. pain in any 
other
 part of the lower extremities, pain radiating to the knee) 
11. Any pharmacological or non-pharmacological treatment targeting OA started or changed 
during
 the 4 weeks prior to randomization or likely to be changed during th e  duration of 
the stud
y 
12. Pregnancy or planning to become pregnant during the study 
13.
 Use of the following medications: 
a. No IA injected medications in the study knee during the study (or 12 weeks prior to 
Baseline). 
b. No a nalgesics containing opi[INVESTIGATOR_2438]. 
c. NSAIDs are not permitted during the study; acetaminophen is available as a rescu e 
m
edication during the study from the provided supply. 
d. No topi[INVESTIGATOR_19529] l treatment on the study knee during th e  study 
e. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study 
(tr
eatment such as low-dose Aspi[INVESTIGATOR_248] (81 mg) and Plavix are allowed) 
f. No s
ystemic treatments that may interfere with safety or efficacy assessments during 
the study 
g. No immunosuppressants 
h. No use  of systemic or intra-articular corticosteroids 
14. No human albumin treatment in the [ADDRESS_296231] incapable of giving informed consent may be enrolled in th e  study. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
28 
  
5 STUDY PLAN AND PROCEDURES 
 
Subjects will be randomized into the  study 6:1 to receive an IA injection  of 4 mL Ampi[INVESTIGATOR_2394]™ 
or 4
 mL saline on Visit 2, Day 0 (Baseline). Telephone contact [CONTACT_243825] 
[ADDRESS_296232] will be followed fo r  12 weeks and the  clinical 
effects of treatment on OA pain will be evaluated during clinic visits at 6 and 12 weeks, and 
during telephone contacts at 2 and 10 weeks, using the WOMAC osteoarthritis Index 3.1 
(pa
in subscore, stiffness subscore and function subscore) an d an overall global severity 
a
ssessment (Patient’s Global Assessment [PGA]). Safety will be assessed by [CONTACT_243826] (through [ADDRESS_296233]-dose and at all follow up in - clinic visits and telephone 
contacts), vital signs (Baseline, and Weeks 6 and 12), recording prior and concomitant 
m
edications including start/stop dates, indication, dose an d frequency (through [ADDRESS_296234]
-dose and at all follow up in-clinic visits and telephone contacts), physical examination 
(B
aseline and Weeks 6 and 12), and laboratory tests (Screening and Week 12). The 
assessments and procedures performed at each subject visit or contact [CONTACT_243827] 
S
ection 5. 1 and in Table 6.1 . 
 
 
5.1 DESCRIPTION OF STUDY VISITS  
 
5.1.1 Visit 1 (Day -7 through Day 0, in-clinic); Screening  
 
The following procedures will be performed at Visit 1 (Screening): 
 
• Obtain written informed consent before the  start of an y  study specific procedure. 
• Review medical history includ ing all  previous treatments fo r  OA. 
• Record prior and concomitant m edications including start/stop dates, indication, dose 
and frequency. 
• Record demographic data includ ing date of birth, gender and race. 
• Measure and record heigh t and weight. 
• Perform  and record physical examination. 
• Record WOMAC Index 3.1, 5-point Likert scale (sections A-C) fo r the  study knee 
• Record WOMAC Index 3.1, 5-point Likert scale (section A only) for  the  contralateral 
kne
e 
• Record PGA 
• Record vital signs. (Measure body temperature, systolic / diastolic blood pressure [BP] 
and pulse rate). 
• Evaluate all inclusion and exclusion criteria to ensure that subjects meet all inclusion 
c
riteria and none of the exclusion criteria. If subject meets all inclusion/exclusion 
c
riteria up to this point, move forward with x- ray and laboratory assessments. 
• Obtain x-ray of study knee and evaluate for KL grade (x-rays within 6 months of the 
screening date are acceptable) 
• Collect blood sample for local laboratory assessment.  
• Collect urine hCG in women of child-bearing potential. Evaluate for pregnancy.  
 
 
  
 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
29 
  
5.1.2 Visit 2 (Day 0, in-clinic) Baseline/Randomization/Trea tment 
 
The following procedures will be performed at Visit 2 (Baseline/Randomization/Treatment): 
 
• Confirm eligibility by [CONTACT_243828]/exclusion criteria from the screening visit 
a
gain at Baseline. Confirm KL grade from Principal Investigator. 
• Perform WOMAC (sections A- C),  using the 5-point Likert scale for the evaluation of 
the
 study knee. Confirm Baseline WOMAC Pain (WOMAC A) and WOMAC 
F
unction (WOMAC C) meet Inclusion #6 and #7 prior to enrollment. 
• Perform  PGA evaluation of the study knee. 
• Record concomitant medications. 
• Perform  and record physical examination. 
• Record vital signs. (Measure body temperature, systolic / diastolic blood pressure [BP] 
and pulse rate) pre- and post-injection. 
• If subject meets all inclusion/exclusion, subject ca n be enrolled into study 
• Perform  intra-articular injection of study drug.  
• Record post-injection AEs if observed. 
• Issue rescue medication (acetaminophen). 
 
5.1.3 Visit 3 (Day 1, telephone contact)  
 
The following procedures will be performed at Visit 3: 
 
• Record AEs. 
• Record concomitant medications. 
• Review rescue medication use. 
 
5.1.4 Visit 4 (Week 2 ± [ADDRESS_296235])  
 
The following procedures will be performed at Visit 4: 
 
• Perform WOMAC (sections A- C),  using the 5-point Likert scale for evaluation of the 
stud
y knee. 
• Perform  PGA evaluation of the study knee. 
• Record AEs. 
• Record concomitant medications. 
• Review rescue medication use. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
30 
  
5.1.5 Visit 5 (Week 6 ± 7 d ays, in-clinic) 
 
The
 following procedures will be performed at Visit 5: 
 
• Perform  and record physical examination. 
• Record vital signs. (Measure body temperature, systolic / diastolic blood pressure [BP] 
and pulse rate). 
• Perform WOMAC (sections A- C),  using the 5-point Likert scale for the evaluation of 
the stud
y knee. 
• Perform  PGA evaluation of the study knee. 
• Record AEs. 
• Record concomitant medications. 
• Review rescue medication use. 
 
5.1.6 Visit 6 (Week 10 ± [ADDRESS_296236])  
 
The following procedures will be performed at Visit 6: 
 
• Perform WOMAC (sections A- C),  using the 5-point Likert scale for the evaluation of 
the stud
y knee. 
• Perform  PGA evaluation of the study knee. 
• Record AEs. 
• Record concomitant medications. 
• Review rescue medication use. 
 
5.1.7 Visit 7 (Week 12 ± 7 days , in-clinic)  
 
The following procedures will be performed at Visit 7: 
 
• Perform  and record physical examination (including weight). 
• Record vital signs. (Measure body temperature, systolic / diastolic blood pressure [BP] 
and pulse rate). 
• Perform WOMAC (sections A- C),  using the 5-point Likert scale for the evaluation of 
the stud
y knee. 
• Perform  PGA evaluation of the study knee. 
• Collect blood sample for local laboratory assessment.  
• Record AEs. 
• Obtain information from subject about medical care for knee OA prior to participation in 
the 
current study (medical history). 
• Record concomitant medications. 
• Review, count, and collect rescue medication. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
31 
  
 
5.1.8 Early Termination Visit  
 
The following procedures will be performed at Early Termination Visit: 
 
• Perform  and record physical examination, including weight. 
• Record vital signs. (Measure body temperature, systolic / diastolic blood pressure [BP] 
and pulse rate). 
• Perform WOMAC (sections A- C),  using the 5-point Likert scale for th e  evaluation  of 
the study knee. 
• Perform  PGA evaluations of the study knee. 
• Collect blood sample for laboratory assessment. 
• Record AEs. 
• Obtain information from subject about medical care for knee OA prior to participation in 
the current study (medical history). 
• Record concomitant medications. 
• Review, count, and collect rescue medication. 
 
5.1.[ADDRESS_296237] misses any scheduled follow up visit and 
cannot be seen prior to the start of th e  visit range fo r  th e  next visit, the visit is considered 
m
issed. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
32 
  
5.1.11 CONCOMITANT MEDICATIONS AND RESCUE MEDICATION  
 
The following medications/therapi[INVESTIGATOR_243791]: 
 
1. No IA injected medications in the study knee during the study. 
2. No analgesics containing opi[INVESTIGATOR_2438]. 
3. NSAIDs may not be used during the study (low-dose Aspi[INVESTIGATOR_248] (81 mg) is allowed). 
Ac
etaminophen is available as a rescue medication during the study from the 
provide
d supply. 
4. No non-pharmacological treatment targeting OA started  or changed during the study. 
5. No topi[INVESTIGATOR_243792] e  study. 
6. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study 
(tr
eatment such as low-dose Aspi[INVESTIGATOR_248] (81 mg) or Plavix is allowed) 
7. No systemic treatments that may interfere with safety or efficacy assessments during 
the study. 
8. No immunosuppressants. 
9. No use of systemic or intra-articular corticosteroids 
10. No human albumin treatment during the study. 
 
Any medication used during the study should be recorded. Al l  co nc o mitant medication start 
and stop dates, total daily dose, route and indication should to be recorded. 
 
The
 only allowed analgesia medication during the 12-week study is [ADDRESS_296238] be reduced if using other medications that 
c
ontain acetaminophen (cold medicines, etc. ). 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017 
Clinical Study Protocol: AP -003-C Confidential    
33 
  
6 METHODS OF ASSESSMENT  
 
Demographic Data 
 
At Visit 1 (Screening), subject demographic data will be co llected.  These include: date of 
birth, gender and race. 
 
Medical History 
 
At Visit 1 (Screening) a complete medical history, including prior interventions to the study 
knee, will be obtained from each subject. 
 
Concomitant Medications 
 
Detailed history of m edications will be documented for each subject at Visit 1 (Screening) 
a
nd Visit 2 (Baseline).  Concom itant medications (especially any changes in medication) will 
be
 documented for each subject at each scheduled visit. 
 
Kellgren-Lawrence Grading Scale 
 
Radiographic images should be evaluated according to the Kellgren-Lawrence Gradin g 
Scale as noted below in F igure 2 . 
 
  FIGURE 2: Kellgren-Lawrence Grading System 
 
Grade   
Description  
 
0  
Normal  knee  without  osteophytes  or joint space narrowing  
 
1  
Possible  osteophytic  lippi[INVESTIGATOR_243793]  
 
2  
Definite  osteophytes  and possible  narrowing  of joint space  
 
3  
Moderate  multiple  osteophytes,  definite  narrowing  of joint space  and some  
sclerosis  and possible  deformity  of bone ends  
 
4  
Large  osteophytes,  marked  narrowing of joint space,  severe  sclerosis and 
definite  deformity  of bone ends  
 
Physical Examination and Vital Signs 
 
Height in feet and inches will be measured at Visit 1 (Screening). 
 
B
ody weight in pounds (lb) will be measured at Visit 1 (Screening) an d at Visit 7 (Week  12 
or Early Termination Visit).  
 
Body temperature (deg F) will be measured at each vis it. 
S
ystolic and diastolic BP and puls e  rate will be measured with the subject in a seated 
posi
tion. 
 
The full physical examination will consist of examining the following body systems: 
cardiovascular, respi[INVESTIGATOR_696], abdom inal, skin and musculoskeletal other than the  knee. The 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017 
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296239] be available to evaluate lab values during the course of the study. 
 
See Table 6.1  for full schedule of assessments and procedures 
 
 
 
6.1 EFFICACY ASSESSMEN TS 
 
Note: Efficacy questionnaire questions will be asked “with reference to study knee” i. e. to 
obtain scores specific for the treated knee. 
 
6.1
.1 WOMAC® Osteoarthritis Index ( Bellamy 1988 ) 
 
WOMAC Index 3.1 (sections A-C), using the 5-point Likert scale, should be com pleted by 
[CONTACT_243829], pre-dose and  pre-aspi[INVESTIGATOR_243794] [ADDRESS_296240] 5  minutes to complete the  questionnaire. 
Subjects are asked about their pain, stiffness, and function in the knee (study  joint) due to 
arthritis during the last 24 hours. 
 
S
ubjects respond to each subscale by [CONTACT_2329] a 5-point Likert score (0 = none, 1 = mild, 2 =  
moderate, 3  = severe, 4 = extreme). 
 
6
.1.2 Patient’s Global Assessment of Disease Severity (PGA)  
 
The PGA should be completed by [CONTACT_216814], pre-dose and pre-aspi[INVESTIGATOR_243795] 0 (prior to injection), and at Weeks 2, 6, 10  and 12. 
 
S
ubjects are asked the following question: “Considering all the ways in which your arthritis  
affects you,  please indicate how you are doing.” 
 
Subjec
ts respond by [CONTACT_2329] a 5-point adjectival Likert score (0 = very well, 1 = well, 2  = fair,  
3 = poor, 4  = very poor). 
 
6.2 SAFETY  PARAMET ERS 
 
Based on results of previous studies of a single intra-articular injection of Ampi[INVESTIGATOR_2394]™ < 5 kDa  
ultrafiltrate of 5% HSA  in adults with OA of the knee in which  no clinically significant 
diff
erences between active and saline were found, safety will be assessed by [CONTACT_44745] 
a
dverse ev e nts, vital signs, results of physical examination, recording prior and concomitant 
medications and safety labs. 
 
 
 
 
 
 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017 
Clinical Study Protocol: AP -003-C Confidential    
35 
  
 
6.2.1 Vital Signs  
 
Vital signs (radial pulse rate, blood pressure, and body tem perature) should be recorded at 
Screening, pre- and post–treatment on Day 0, and then on visits at Weeks [ADDRESS_296241] meets all other inclusion/exclusion criteria at Screening; Blood draws 
should be
 done at Week 12 after al l  WOMAC an d PGA assessments are completed.  All 
clinically significant values will be followed up at the Investigator’s discretion . Blood 
laboratory results must be reviewed and compared to reference ranges throughout the study to 
evaluate for potential adverse events. Blood draws will be performed in co m pliance with 
standard laboratory procedures.  
 
The following analysis will be conducted by [CONTACT_12082]: 
 
Serum biochemistry: Sodium, potassium, chloride, bicarbonate, glucose, urea, creatinine, 
creatine kinase, urate, phosphate, total calcium, cholesterol, albumin, globulins, protein, total 
bil
irubin, conjugated bilirubin, gamma glutamyltransferase (GGT), alkaline phosphatase 
(ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate 
de
hydrogenase (LD). 
 
Hematology: Hemoglobin, red blood cell count, hematocrit, mean cell volume (MCV), mean 
cell hem oglobin (MCH), mean cell hemoglobin concentration (MCHC), platelets, white cell 
count, neutrophils, lymphocytes, monocytes, eosinophils, and basophils. 
 
In addition to the tests stated above, all female subjects with child-bearing potential will be 
tested for
 serum hCG (for exclusion #12/pregnancy). 
 
36 
 Ampi[INVESTIGATOR_2394]™ Versio n 1.3    09 November 2017  
Clinical Study Protocol: AP- 003-C Confidential  
 
 
 
TABLE 6.[ADDRESS_296242] be acquired at Scr eening to satisfy inclu sion criteria #5.  X-rays obtained within [ADDRESS_296243] previously sought out treatment for OAK prior to this study  
*Includes height and weight at Screening (Visit 1) and Week 12 (Visit 7) 
   
 
 
Screening 
VISIT [ADDRESS_296244]-treatment 
check 
(telephone 
contact) 
VISIT 3   
 
Week 2 
(telephone 
contact) 
VISIT 4   
 
Week 6 
VISIT 5  
 
Week 10 
(telephone 
contact) 
VISIT 6  
 
Week 12 
Final Visit  
VISIT 7  
 
 
Early Terminati on 
Visit 
# Day 
# 1 
Day-7 to 0 2 
Day 0 3 
Day 1 4 
Day 14  ± 7 5 
Day 42  ± 7 6 
Day 70  ±7 7 
Day 84  ± 7  
Informed Consent X        
Inclusion/exclusion criteria X X       
Medical hist ory/prior medications2  
X      X X 
Concomitant medications   
X  
X  
X  
X  
X  
X  
X  
X 
Physical examination*  X* X   X  X* X* 
Vital Signs X X
=   X  X X 
Randomization  X       
WOMA C A-C, 5-point Likert Scale X X  X X X X X 
 
Patient’s global assessment (PGA)   
X  
X   
X  
X  
X  
X  
X 
X-ray1 X        
Clinical laboratory tests X      X X 
Treatment with stu dy drug  X       
Rescue medication di spensed/collected   X     X X 
Review Rescue medication   X X X X X X 
Adverse Events  X X X X X X X 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November 2017  
Clinical Study Protocol: AP -003-C Confidential    
37 
  
 
7 DISCONTINUATION CRITERIA  
 
7.1 EARLY DISCONTINUATIO N OF THE STUDY  
 
It is agreed that for reasonable cause, either the investigator or the Sponsor may terminate 
thi
s study, provided a written notice is submitted at a reasonable time in advance of intended 
termination; if by [CONTACT_243830], Inc., 
a
nd if by [CONTACT_1034], notice will be provided to each investigator. 
 
If a severe local reaction or drug-related SAE occurs at any time during the study, the Safety 
Monitoring Committee will review the case immediately. 
 
The study will be immediately suspended and no additional Ampi[INVESTIGATOR_243796] l  appropriate study data by [CONTACT_3433] e  SM C  if 1 or more subjects 
de
velop any of the following adverse events deemed to be possibly, probably, or definitely 
related to A mpi[INVESTIGATOR_243797]/or Medical Monitor, based upon close temporal 
re
lationship or other factors: 
 
• Death 
• Anaphylaxis (angioedem a, hypotension, shock, bronchospasm, hypoxia, or 
re
spi[INVESTIGATOR_1506]) 
• Induction of autoimmune arthritis 
• Hepatic failure 
• Aplastic anemia. 
 
The study will not be restarted until all parties have agreed to the course of action to be taken 
and the IRB/EC has been notified. 
 
7.2 EARLY DISCONTINUATION OF INDIV IDUAL SUBJECTS  
 
Subjects are to be withdrawn from the study fo r  an y  of the following reasons: 
 
• Withdrawal of informed consent 
• Subject is lost to follow up. 
 
Subjects will also be withdrawn at any time if the investigator concludes that it would be in 
the subject’s best interest for any reason.  Protocol violations do not lead to subject 
withdrawal unless they constitute a significant risk to the subject’s safety. 
 
S
ubjects can voluntarily withdraw from the trial for any reason at any tim e. They are to be 
considered withdrawn if they state an intention to  withdraw, fail to return for visits, or 
be
come lost to follow up for any reason. Subjects withdrawing from the study because of an 
AE should be followed for at least [ADDRESS_296245]. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
38 
  
8 TREATMENT  
 
Eligible subjects will be randomized (6:1) to a single [ADDRESS_296246] satisfies the requirem ents for the study (see inclusion criteria 6 - 7) as the study knee.  At 
the time of dose administration, the study knee should be treated with received 
investigational product in accordance with the randomization schedule.  The other knee 
sho
uld receive standard of care. 
 
Aspi[INVESTIGATOR_243798]. Aspi[INVESTIGATOR_243799]/eCRF. The study treatment 
should be administered as an injection into the knee joint space under sterile prep conditions, 
(i.e
. prior to injection, th e  knee should be cleaned with an antiseptic).   
 
The
 recommended procedures is to administer the injection into the knee joint space with the 
sub
ject in th e  seated position with the treatment knee flexed at 90° . The area of injection is 
inferior lateral to the patella; lateral level of the  join t line.   
 
The Principal Investigator [INVESTIGATOR_243800] a 
topi[INVESTIGATOR_243801]. Injection of lidocaine prior to th e  Ampi[INVESTIGATOR_243802] t  allowed.   
 
The needle should be passed through the fat pad to the firm su rface of the intercondylar 
notch. Following th e  withdrawal of th e  needle, it is recommended that fingertip pressure be 
applied to the injection site, and then a sterile dressing (BandAid) is used to cover the 
i
njection site. Injection should proceed easily.  
 
The recommended needle for this injection is a 25-gauge needle that is 1.[ADDRESS_296247] should be documented as a potential non-inter-articular injection. The 
injector and date of administration should be recorded in the study source notes/eCRF. 
 
Subjects should be advised to abstain from submersing their knee in water for at least 24 
hours (swimming pool, baths, lakes, ect.).  Showering is acceptable. 
 
8.2 DRUG STORAGE AND ACCOUNTABILITY 
 
Study drug should be stored at room temperature (59º – 77ºF or 15º – 25ºC) in a secure area 
with re
stricted access and temperature monitoring.  A temperature monitor calibration must 
be provided to the CRO prior to receiving study drug. 
 
 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296248] is to be dispensed in accordance with the Investigator’s 
pre
scription and it is the Investigator’s responsibility to ensure that an accurate record is 
m
aintained of investigational product issued and returned. 
 
If any quality issue is noticed upon the receipt or us e  of an investigational product (i.e. 
deficiencies in condition, packaging, appearance, associated do cum entation, labeling, expi[INVESTIGATOR_151273], temperature, etc.), Ampio Pharmaceuticals, Inc. must be promptly notified.  
Tem
perature monitors, and instructions to download the temperature data to Ampio 
P
harmaceuticals, Inc., will be included with ea ch site shipment of study drug. 
 
Under no circumstances may the Investigator supply investigational product to a third party, 
a
llow the investigational product to be used other than as directed by [CONTACT_243831], or dispose of investigational product in any other manner. 
 
All investigational product, used or unused during the study, must be retained in the study kit 
unti
l notification from Ampio or designated representative. Ampio, or designated 
representative will ins truct sites on study drug returns and/or destruction of study drug. 
 
[ADDRESS_296249] each vial to ensure full injection 
volu
me was used.  Compliance with treat ment is thus assured. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
40 
  
9 ADVERSE EVENTS  
 
9.1 DEFINIT ION OF AN ADVER SE EVENT  
 
An adverse event (AE) is defined as any undesired medical occurrence in a subject or clinical 
investi
gation subject receiving a phar m aceutical product and which does not necessarily have 
a
 causal relationship with this treatment. An AE ca n therefore be any unfavorable sign and 
unintended sign (including an abno rmal laboratory finding), symptom, or disease temporarily 
associated with the use of a study drug, whether or not related to th e  study drug. 
 
Asse
ssment of severity of an AE will be rated according to categories listed in T AB LE 9.1. 
 
TABLE 9.1 DEFINITIONS OF AE S EVERI TY 
 
Grade  1 (MI LD): 
The symptom is barely noticeabl e to the study subject and does  not influence performance or functioning. 
Concomitant medication is not ordinarily indicate d for relief of mild AE s. 
Grade 2 (MODERATE):  
The symptom is of sufficie nt severity to make the study subject uncomfortable and to influence  performance 
of daily activities.  Concomitant medicatio n may be indica ted for relief of moderate AEs. 
Grade 3 (SEVERE):  
The sy mptom  causes sev ere disco mfort, sometimes of such severity  that the study subject cannot continue in 
the study. Daily activities are significantly impaired or prevented by [CONTACT_4167]. Concomitant medication 
may be indica ted for relief of sever e AEs.  
 
Determination of the relationship between the AE and the study drug will be made using the 
guidelines
 presented in  TABLE 9.2. 
 
TAB
LE 9.2 G UIDE LINES FOR DETERMINING THE RELATIONSHIP (IF ANY) 
BETWEEN ADVERSE EVENT AND THE STUDY DRUG  
 
Unrelated  The adverse event is unlikely to have been caused by [CONTACT_5349]. 
Possib ly related  It is unclear  whether the adverse event may have  been caused by [CONTACT_5349]. 
Related  The adverse event is likely to have  been caused by [CONTACT_5349]. 
 
 
9.2 DEFINIT ION OF A SERI OUS ADVERSE EVENT  
 
A Serious Adverse Event (SAE) is any untoward medical occurrence that occurs at any dose 
tha
t: 
 
• Results in death 
• Is life-threatening (subject is at immediate risk of death from the event as it occurred) 
• Requires in-patient hospi[INVESTIGATOR_059] (formal admission to a hospi[INVESTIGATOR_113979]) or 
prolonga
tion of existing hospi[INVESTIGATOR_059] 
• Results in persis tent or significant disability/incapacity 
• Results in a congenital anomaly/birth defect 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296250] ING OF ADVERSE EVEN TS AND SERIOUS ADVERSE 
EVENTS  
 
Recording and reporting of adverse events should be in accordance with the  FDA fina l 
“Guidance for Industry and Investigators Safety Reporting Requirements for INDs and 
BA/BE Studies” of December 2012. 
 
Any AE is to be recorded in the eC R F. In order to avoid  vague, ambiguous, or colloquial 
expressions, the  AE should be rec orded in standard medical terminology rather than the 
subject’s own words.  Whenever possible, the investigator should combine signs and 
symptom s that cons titute a single diagnosis. 
 
The existence of an AE may be concluded from a spontaneous report of the subject; from the 
ph
ysical examination; or from special tests e.g., laboratory assessments, where applicable, or 
othe
r study-specified tests (source of AE). 
 
The
 reporting period begins from the time that the subject receives IA injection at the 
B
aseline visit through subject’s Final Visit at [ADDRESS_296251] also be re cor ded. 
 
9.3.1 AE Follow up 
 
All AEs occurring during the study ar e  to be followed up in accordance with good medical 
practice until they are resolved, stabilized or judged no longer clinically significant o r, if a 
chronic condition, until fully characterized.  Any AEs that are considered drug-related 
(possibly
 related, definitely related) must be followed  for 30 days, or to resolution, or until no 
i
mprovement is expected, whichever occurs firs t. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
42 
  
9.3.2 Overdose  
 
No information on treatment of overdose of Ampi[INVESTIGATOR_243803]. However, it is 
comm
on medical practice to administer 5% HSA, the sole starting material of Ampi[INVESTIGATOR_2394], in 
multiple infusions until hemorrhage is controlled thereby [CONTACT_243832][INVESTIGATOR_2394].  
 
In the  case of overdose, the subject should be followed as for an AE and approp riate 
supportive medical treatment instigated. 
 
9.[ADDRESS_296252]
udy personnel. It is important that the investigator provide his/her assessment of 
re
lationship to study drug at the time of the initial report. Entry of an SA E  into  the eCRF 
trigg
ers an automatic alert to the CRO safety team. The  following information must be 
re
ported: 
 
• Protocol number 
• Site and/or Investigator number 
• Subject number 
• Demographic data 
• Brief description of the event 
• Onset date and time 
• Resolution date and time, if the event resolved 
• Current status, if event not yet resolved 
• Any concomitant treatment and medication 
• Investigator’s assessment of whether th e  SAE wa s  related to Inv estigative product or 
not. 
 
The CRO Safety Associate will con tact the site for cla rification of data entered onto the 
eCRF, or to obtain missing information.  In the event of questions regarding SAE reporting, 
the site may contact [CONTACT_243833] 9.4.2. 
 
9.4.2 SAE Information  
 
Ampio Pharmaceuticals Inc., or their designee CR O, is responsible for submitting reports of 
AEs associated  with the  use of the drug that are both serious and  unexpected  to FDA 
a
ccording to 21 CFR 312.32 and the final guidan ce (2012). All investigators participating in 
ongoing clinical studies with the study medication will receive copi[INVESTIGATOR_243804] (IRB) or Et hics committee (EC). 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
43 
  
10 STATISTICAL METHODS  
 
10.1 GENERAL CONSIDERATIONS  
 
This section describes the rules and conventions to be used in the  presentation an d analysis of 
the data.  A comprehensive presentation of the data management and statistical analysis plan 
will be approved by [CONTACT_243814], Inc., prior to stu dy com pletion. 
 
10.1.1 Statistical and Analytical Plan:  
 
This is a randomized, confirmatory study in subjects with severe OA (KL 4) of the knee. 
Subjects will be followed over a 12-week treatment period to assess the efficacy of 
Ampi[INVESTIGATOR_2394]™ on cha
nges in pain, stiffness and function, and patient satisfaction (PGA) and to 
assess the safety of Ampi[INVESTIGATOR_2394]™ by [CONTACT_12902]. 
 
A wit
hin-patient, multi-component endpoint, OMERACT-OARSI responder analysis, 
evaluating pain, function, and PGA, will be used as primary analysis for this study. 
The saline group in this study is designed to maintain a blind the study is not powered to 
make inference about patients receiving saline; therefore, the results from patients receiving 
saline will be summarized but no comparisons or inferences will be made. 
 
10.[ADDRESS_296253]
-OARSI responder at 12 weeks after a single 4 mL Ampi[INVESTIGATOR_2394]™ intra-articular 
inj
ection at Baseline. 
OMERACT-
OARSI response is evaluated by: 
A patient in this study will be considered a responder for the purpose of efficacy analysis if the 
following criteria is met. 
1) The patient has:  
a. a percent improvement in pain (WOMAC pain) from baseline of ≥50% and an 
absolute change in pain from baseline of ≥ 1 point; or  
b. a percent improvement in function (WOMAC function) from baseline of ≥50% and 
an absolute change in function from baseline of ≥[ADDRESS_296254] meet the criterion below to be considered a 
re
sponder. 
2) The patient demonstrates improvement in at least 2 of the following: 
a. Improvement in pain (WOMAC pain) over baseline of ≥20% and a 0.5-point 
absolute change in pain 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
44 
 b. Improvement in function (WOMAC function) over baseline of ≥20% and a 0.5-
point absolute change in function 
c. Improvement in patient global assessment (PGA) over baseline of ≥20% and a 0.5-
point absolute change in PGA 
The second statistical objectives are to: 
 
˗ Eva luate the improvement in the composite endpoint of pain and function (WOMAC A 
and WOMAC C) from Baseline to Week 12  
- Evaluate the improvement in patient global assessment (PGA) from Baseline to Week 
12  
- Eva
luate improvement in the composite endpoint of pain and function (WOMAC A and 
C) compared to saline from all single-injection Ampi[INVESTIGATOR_243784]. 
 
The composite endpoint of pain and function (WOMAC A and WOMAC C) will be evaluated 
using a “controlled” OMERA CT-OARSI responder criteria, defined as: 
 
 I mprovement in pain and function (WOMAC A and WOMAC C) over baseline of 
≥20% and a 0.5 point absolute change 
Improvement in patient global assessment will also follow OARSI’s recommendation for a 
clinically meaningful improvement, defined as: 
 
 Improvement in patient global assessment (PGA) over baseline of ≥20% and a 0.5 
point absolute change in PGA 
 
10.3 ANALYSIS POPULATIONS  
 
10.3.1 Safety Analy sis Population:  
 
The safety analysis population is defined as al l  subjects wh o  receive study medication 
(Ampi[INVESTIGATOR_243805]). Subjects w ill be analyzed as treated. 
 
1
0.3.2 Intent-to-treat Population:  
 
The intent- to-treat (ITT) analy sis population is defined as all subjects who are randomized, 
re
gardless of whether or not they have received the  investigational product, or have a post- 
baseline vi sit. All efficacy analys es will be performed in the ITT population. Subjects will 
be analyzed as treated. 
 
1
0.3.3 Per Protocol Population:  
 
The per protocol analysis population is defined as all subjects included in the ITT analysis 
who met all entry criteria, completed the Week [ADDRESS_296255]-OARSI criteria, the following hypothesis will be tested. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
45 
  
H0:π ≤ π 0 versus H A:π > π 0      
 
Where π 0 is the hypothesized value for the proportion of responders.  The value will be 30% 
in this study.  This test will be tested using an exact binomial test.  That is, given the sample 
siz
e of n, the number of responders X, and the value of π 0 =0.30, then probability that X or 
more
 events would be observed will be calculated as the p-value.  Since this is a one sided 
test, the alpha level will be 0.025. 
 
The primary hypothesis and these secondary hypotheses will be tested in a hierarchical 
manner with the primary first and the secondary hypotheses in the order listed.  Using this 
approach, there is no adjustment necessary in the overall significance level.  All testing will 
be
 conducted using an overall significance level of 5%.  If the tests are one sided, the 
significance level will be 2.5%. 
 
The secondary endpoints are represented by [CONTACT_243834]
d by [CONTACT_243835]: 
 
- Improvement in pain and function (WOMAC A and WOMAC C) over baseline of 
≥20% and a 0.5 point absolute change 
 
- Improvement in patient global assessment (PGA) over baseline of ≥20% and a 0.5 point 
absolute change in PGA 
 
- Improvement in pain and function (WOMAC A and WOMAC C) over baseline of 
≥20% and a 0.[ADDRESS_296256] two secondary endpoints are identical and are: 
 
H0:π
 ≤ 30%  versus H A:π  > 30%      
 
These will be tested using the exact binomial test. 
 
The hypothesis for the third secondary endpoint will be tested as: 
 
H0:πA ≤ π HS versus H A: πA > π HS 
 
W
here π A is the response rate from Ampi[INVESTIGATOR_243806] π HS is the response rate of the 
sa
line control from previous single-injection Ampi[INVESTIGATOR_243784].  This will be tested using 
Fisher’s exact test. 
 
10.3.5 Exploratory Endpoints  
 
None 
 
10.3.6 Definition of Study Visits  
 
This clinical trial has a total of  7 study visits, including telephone contacts, during the 12-
we
ek study (see Table 6.2).  The time on study for each subject observation will be defined 
relative to Day 0/Baseline, the day of the initial dose. For  analysis, the  Baseline measure is 
the la
test measure prior to initiation of treatment. 
 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
46 
 10.3.7 Number of subjects to receive study drug 
 
A total of approximately 171 subjects (146 Ampi[INVESTIGATOR_2394]; 25 Saline) will be enrolled in the study 
to a sing
le (1) intra-articular injection of 4 mL Ampi[INVESTIGATOR_243790] 4 mL saline (6:1). 
 
Since the sample size for adequate power of th e  primary and second secondary hypotheses 
is a
lmost identical given the anticipated results of previous studies, the sample size for this 
study is based on the following hypothesis.  
 
H0:π
 ≤ 30%  versus H A:π > 30%     
 
A sample size of 146 patients yields a greater than 90% power of rejecting the null 
hypothesis when the anticipated proportion under the alternative hypothesis is 45%.  
 
1
0.3.8 Disposition of subjec ts 
 
Disposition of subjects, including study completion status and response to therapy as 
m
easured by [CONTACT_81560] A, WOMAC C and PGA subscores, will be summarized by [CONTACT_135911], race, an d  gender fo r each of th e  analysis populations. 
 
10.3.9 Interim analys is 
 
There will be no interim analysis. 
 
1
0.3.10 Blinding and randomization  
 
All subjects will be randomized 6:[ADDRESS_296257] the planned 
a
nalysis. 
 
10.3.11 Data presentation  
 
[IP_ADDRESS] Demograp hic and Baselin e Char acteristics:  
 
Demographic (e.g., age, sex, race, and ethnicity) and Baseline characteristics (e.g., weight, 
height, prior injection of another intra-arterial therapeutic for OA of the knee) summarized 
using
 descriptive statistics, overall and by [CONTACT_243836] r the ITT analysis population. 
 
[IP_ADDRESS] Medical His tory and Physical Examination:  
 
The number and percent of subjects with past and current medica l disorders at the t ime of 
ra
ndomization will be presented overall for the ITT analysis populati on. Results of any 
abnormalities documented from the abbreviated physical examination at Baseline and Week 
12, will
 be summarized overall for the safety and ITT analys is populations. 
 
[IP_ADDRESS] Concomitant Medicati ons or Treatments:  
 
The number and percent of subjects receiving conco mitant medications or treatments prior to 
a
nd during the study and at the final visit will be tabulated an d  presented overall for  the ITT 
Ampi[INVESTIGATOR_2394]™  Version 1. 3 09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
47 
 analysis population.  Concomitant medications/treatments will be summarized using 
de
scriptive statistics an d will be presented by [CONTACT_243837] (WHO DRUG classification) 
ove
rall for the safety and ITT analysis populations. 
 
1
[IP_ADDRESS] Safety data:  
 
Safety data will be evaluated by [CONTACT_243838], physical exam, 
labor
atory analysis, and the frequency and severity of AEs. Concomitant m edication will 
be recorded for safety. 
 
Adverse events: 
 
The Investigator is responsible for monitoring the safety of subjects who have enrolled in the 
stud
y. All AEs considered related, or possibly related to Ampi[INVESTIGATOR_2394]™, will be followed until 
the e
vent resolves or s tabilized without further change. Subjects will b e followed for the 
occurrence of AEs until [ADDRESS_296258] day of treatment through th e  en d  of study. AEs should be 
properly documented on the appropriate CRF pages. 
 
The severity of AEs (mild, moderate, severe), relatedness (related, possibly related, 
unre
lated) along with the duration, action taken, and outcom e (e.g., study withdrawal) will 
a
lso be recorded.  In addition, event s meeting the criteria of a Serious Adverse Event (SAE) 
must
 be reported to the Sponsor within [ADDRESS_296259] relationship to study drug and/or 
severity. 
 
For the primary effectiveness endpoint (WOMAC A, WOMAC C, and PGA), missing Week 
[ADDRESS_296260] (WOCF) will be selected as the primary method of imputing missing 12 
Week data. Alternate imputation methods employed will include multiple imputations ( SAS 
PROC MI an d SAS PROC MIANALYZE) an d Last Observation Carried Forward (LOCF). 
These sens itivity analyses will be conducted for the primary effectiveness endpoint, to ensure 
that the primary method of imputation chosen is robust with respect to imputation method 
u
sed. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November 2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296261] Operating 
P
rocedures (SOPs) that m ee t the guidelines provided by [CONTACT_66960] (ICH) for Good Clinical Practice in clinical studies. 
 
1
1.3 INSTITUTIONAL REVIE W BO ARDS/ETH ICS COMMITTEES  
 
Before implementing this study, the protocol, the  proposed subject informed consent form s 
a
nd other information for the subjects, must be reviewed by a properly con stituted co mmittee 
or committees responsible for approving clinical studies. The IRB/IEC written, signed 
approval letter/form must contain approval of the  designated investigator, the protocol 
(identifying protocol title, date and version number), and of the subject informed consent 
for
m (date, version). 
  
An
y change or addition to the protocol can only be made in a written protocol amendment, 
which must be approved by [CONTACT_1034], the IRB/IEC and the Hea lth Authorities. 
 
[ADDRESS_296262] of all pertinent aspects of the trial including 
the written information approved/favorably assessed  by [CONTACT_3433] e  IRB/IEC. 
 
Prior to the start of the pre-study examination, the written informed consent form mu st be 
signed and personally dated by [CONTACT_243839] 
c
onsent discussion. One copy of the written information and signed consent form mu st be 
given to each subject and [ADDRESS_296263] be retained in the investigator' s stu dy records. 
 
[ADDRESS_296264] number, and by [CONTACT_5657]/her initials 
I
f, as an exception, it is necessary for safety or regulatory reasons to identify the subject, all 
parties are bound to keep this information confidential. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November 2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296265] 
participating in the trial is violated.  Likewise, the appropriate measures shall be taken to 
pre
vent access of non-authorized persons to the trial data. 
 
11.7 COLLECTION, MONITORI NG AN D AUDITING STUDY 
DOCUMENTATION, AND DATA STORAGE  
 
11.7.1 Collection of Dat a and Monitoring Procedures  
 
This study will use a 21 CFR Part 11 compliant electronic data capture system (eDC). An 
elec
tronic case report form (eCRF) is used for data recording. All data requested on the 
e
CRF must be entered and all missing data must be accounted for. 
 
The data will be checked for completeness and correctness as i t i s entered by [CONTACT_3433] e  real- time 
onl
ine checks applied by [CONTACT_243840]. Off-line checks will also be run to perform any 
additional data review required.  Discrepancy reports will be generated accordingly and 
tra
nsferred to the study center for resolution by [CONTACT_15009]/her designee. 
 
Accurate and reliable data collection will be assured by [CONTACT_89836]–check of the 
e
CRF against the investigator’s records by [CONTACT_11200] (source document verification), 
and the maintenance of a study drug–dispensing log by [CONTACT_243841]. 
 
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Sponsor 
re
presentative will review the protocol and case report form s with the investigators and their 
staff.  During the study a monito r will visit the site regularl y to check the completeness of 
subject records, the accuracy of entries on the  case report form s, the a dherence to the 
protocol and to Good Clinical Pract ice and the  progress of enro llm ent. The monitor will 
e
nsure during on-site visits that study medication is being stored, dispensed and accounted 
for according to specifications. Key trial personnel must be available to assist the monitors 
dur
ing these visits. 
 
The
 investigator must give the monitor access to relevant hospi[INVESTIGATOR_893], to 
confirm their consistency with the case report form entries.  No information in these records 
about the identity of the subjects will leave the study center. Monitoring standards require 
full verification for the presence of informed consent, adherence to the inclusion/exclusion 
criteria, documentation of SAEs and the recording of primary efficacy and safety variables. 
Additional checks of the consistency of the  source data with the eCRFs are performed 
according to the study-specific monitoring plan. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November 2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296266] an audit or an inspection (during the study or after its completion) to evaluate 
compliance with the protocol and the  principles of Good Clinical Practice. 
 
The investigator agrees that representatives of the  Sponsor an d  Regulatory Authorities will 
have direct access, both during and after the course of this study, to audit and review all 
study-relevant medical records. 
 
11.7.[ADDRESS_296267]'s file. Data without a written or electronic record w ill 
be defined before trial start and will be recorded directly on the case report forms, which will 
be
 documented as being the source data. 
 
[ADDRESS_296268] ly confidential.  No disclosure shall be made except in ac cordance 
with a right of publication granted to the investigator. 
 
No information about this study or its progress will be provided to anyone not involved in the 
study other than to Ampio Pharmaceuticals, In c. or its autho rized representatives, or in 
confidence to the IRB, or similar committee, except if required by [CONTACT_2371]. 
 
1
1.9 DISCONTINU ATION OF THE STUDY  
 
It i
s agreed that, fo r reasonable cause, either the investigato r or Ampio Pharmaceuticals, Inc., 
m
ay terminate the investigator’s participation in this study after submission of a written 
notice.  Ampio Pharmaceuticals, Inc., may terminate the study at any time upon immediate 
noti
ce for any reason, including the Sponsor’s belief that discontinuation of the study is 
necessary for the safety of subjects. 
 
1
1.10 STUD Y REPORT, PUBLICATION POL ICY AND ARCHIVING OF 
STUD Y DOCUMENTAT ION 
 
11.10.1 Study Report and Publication Policy  
 
An 
ICH-compliant integrated clinical and statistical report will be prepared upon completion 
of the study and data analysis. The  results of th e  study will be published in a relevant peer- 
re
viewed journal, with authorship status an d ranking designated according to the 
ac
knowledged contributions of participating investigators, institutions an d  the Sponsor. 
Ampi[INVESTIGATOR_2394]™  Version 1.3         09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296269] in the  study, consisting of 
a
ll demographic and medical information, questionnaires, including laboratory data, 
ra
diology data (as applicable), etc., and keep a copy of the signed informed consent form.  
All information on the e-case report forms must be traceable to these source documents in 
the subje
ct's file. 
 
Data without a written or electronic record will be defined before trial start and will be 
re
corded directly on the e- case report forms, which will be documented as being the source 
data. 
 
11.10.[ADDRESS_296270] be retained by [CONTACT_198672] r  as lon g as 
needed to comply with national and international regulations. The Sponsor will notify the 
investi
gator(s)/institution(s) when the study-related records are no longer required. The 
investi
gator agrees to adhere to the document retention procedures by [CONTACT_12142]. 
Esse
ntial documents include: 
 
• IRB/IEC/REB approvals for the study protocol and all amend ments 
• All source documents and laboratory records 
• CRF copi[INVESTIGATOR_014] (electronic copi[INVESTIGATOR_85309] a CDROM) 
• Subjects' informed consent forms (with study number and title of tria l) 
• FDA form 1572 
• Any other pertinent study documents. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
52 
  
12 REFERENCES 
 
1. Akinc i A. Predictive factors and clinical biomarkers for treatment in patients with 
chronic pain caused by [CONTACT_243842] a central sensitization component. 
International Journal of Clinical Practice . 2016; 70; 31-44. 
 
2. B ar-Or D. The filamentous actin cytoskeleton organization and the endothelial cell 
barr
ier. Crit Care Med. 2013 Feb;41(2):686-7. 
 
3. B ar-Or D, Bar-Or R, Rael LT, et al. Heterogeneity and oxidatio n status of commercial 
human albumin preparations in clinical use. C rit Care Med .  2005;33:1638-41. 
 
4. B ar-Or D, Thomas GW, Bar-Or R, et al. Commercial human album in preparations for 
clinical use are immunosuppressive in vitro. Crit Care Med . 2006;34:1707-12. 
 
5. B ar-Or D, Rael LT, Thomas GW, Brody EN. Inflammatory pathways in knee 
osteoa
rthritis: potential targets for treatment. Curr Rheumatol Rev. 2015. 
 
6. B ar-Or D, Thomas GW, Rael LT, Gersch ED , Rubinstein P, Brody E.  Low Molecular 
W
eight Fraction of Commercial Human Serum Albumin Induces Morphologic and 
Tr
anscriptional Changes of Bone Marrow-Derived Mesench yma l Stem Cells. Stem Cells 
Translational Medicine . 2015; 4: 1-11. 
 
7. B ar-Or D, Slone DS, Mains CW, Rael LT. Dipeptidyl peptidase IV activity in 
commercial solutions of human serum albumin. Anal Biochem . [ADDRESS_296271] 1;441(1):13-7. 
 
8. Bellam y N, Buchanan WW, Goldsmith CH et al.  Validation study of WOMAC: a health 
status instrument for measuring clinically important patient relevant outcomes to 
anti
rheumatic drug therapy in subjects with osteoarthritis of the hip or knee. J Rheumatol . 
1988 De
c;15(12):1833-40. 
 
9. C isternas 2016, Royal College of Physicians of London, (1993). // Center fo r  Disease 
C
ontrol and Prevention, Arthritis // Litwic, A., Dennison, E., Cooper, C. 2013, 
Epi[INVESTIGATOR_243807]. Br  Med Bull . (2013); 105: 185-199. 
 
10.
 Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the  United 
States: arthritis data from the Third National Health and Nutrition Examination Survey 
1991-94. J Rheumatol . 2006 Nov;33(11):2271-9. 
 
11. Dworkin et al . The Journal of Pain, Vol. 9, No 2, 2008 
 
12. Evans TW. Review article: albumin as a drug – biological effects of albumin unrelated to 
onc
otic pressure. Alimen t Pharmacol Ther .  2002;16  (Suppl. 5); 6-11. 
 
13. Felson DT, Anderson JJ, Naimark A, et al.  Obesity and knee osteoarthritis: The 
Framingham study. Ann Int Med. 1988;109:18-24 
 
14.
 Frederick ED, Hausburg MA, Thomas GW, Rael LT, Brody E, Bar- Or D. The low 
mol
ecular weight fraction of human serum albumin upregulates C OX2 , prostaglandin E2, 
and prostaglandin D2 under inflammatory conditions in osteoarthritic knee synoviocytes. 
Bioc
hemistry and Biophysics Reports . 2016; (8) , pp. 68-74. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
53 
  
15. Greco et al. The American Journal of Sports Medicine, Vol . 38, No. 5. 2010  
 
16. Guccione AA. Arthritis and the process of disablement. Phys Ther . 1994 Ma y;74(5):408- 
14. 
 
17.
 Kraus V. Direct in vivo evidence of activated macrophages in human osteoarthritis. 
Osteoarthritis and Cartilage.  2016; 24(9):1613-1621. 
 
18.
 Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects 
models. J Biopharm Stat . 200 1 Feb-May;11(1-2):9 -21. 
 
19. Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ , de la Serna AR, Naranjo A, 
Gimeno M, Herrero-Beaumont G; AMELIA study group.  A 40-month multicentre, 
randomized placebo- con trolled study to assess the efficacy and  carry-over effect of 
repeated intra-articular injections of hyaluronic acid in knee osteoar thritis: the AMELIA 
project. Ann Rheum Di s.  2011;70:1957-62.  
 
20. Ohnuma K, Inoue H, Uchiyam a M, Yamochi T, Hosono O, Dang NH, Mori moto C. T- 
c
ell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol . 
2006;16(1)
:3-13. 
 
21.
 Peterfy C.G., M.D. Ph.D., Guermazi A M.D., S. Zaim M.D., P. F. J. Tirman M.D., Y. 
Miaux M.D., D
. White Ph.D., M. Kothari Ph.D., Y. Lu Ph.D., K. Fye M.D., S. Zhao 
P
h.D. H. K. Genant M.D.  Whole-Organ Magnetic Resonance Imaging Score (WORMS) 
of the kne
e. Oste oArthritis and Cartilag e (2004 ) 12, 177–190. 
 
22.
 Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties an d therapeutic 
potential. Hepatology . 2005;41:1211-1219. 
 
23. Rutjes A, Juni P, et al. Viscosupplementation for Osteoarthritis of the Knee. Annals of 
Inte
rnal Medicine . 2012; 157:180-191. 
 
24.
 Shimonkevitz R, Thomas GW, Slone DS, et al. A diketopi[INVESTIGATOR_243808] T- lym phocyte cytokine production through  Rap1. J  Trauma. 
2008;64:
35-41. 
 
25.
 Thomas GW, Rael LT, Hausburg M, Frederick ED, Brody E, Bar-Or D.  The Low 
Molec
ular Weight Fraction of Commercial Human Serum Albumin Induces Acetylation 
of α
-Tubulin and Reduces Transcyto sis in Retinal Endothelial Ce lls. Bioc hemical and 
Biophysical Research Communications . 2016 S ep 30;478(4):1780-5. 
 
26. Thomas GW, Rael LT, Hausburg M, Frederick ED, Mains CW, Slone D, Carrick MM, 
Bar-Or D. The low molecular weight fraction of human serum alb umin upregulates 
production of 15d-PGJ(2) in Peripheral Blood Mononuclear Cells. Biochem Biophys Res 
C
ommun. 2016 May 13;473(4):1328-33. Epub 2016 Apr 16. 
 
27.
 Thomas GW, Rael LT, Mains CW, Slone D, Carrick MM, Bar-Or R, Bar-Or D. Anti- 
I
nflammatory Activity in the Low Molecular Weight Fraction of Commercial Human 
Serum Albumin (LMWF5A). J Immunoassay Immunochem. 2016;37(1):55-67. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
54 
  
28. Vincent JL, Navickis RJ, Wilkes MM .  Morbidity in  hospi[INVESTIGATOR_243809]: A meta-analysis of randomized, controlled trials* C rit Care Med. 
2004;32:
2029–38. 
 
29.
 Zhang W, Nuki G, Moskowitz R.W. et al.  OARSI recommendations for the management 
of hip a
nd knee osteoarthritis Part III: changes in evidence following systematic 
cum
ulative update of research published through January 2009. Osteoarthritis and 
Cartilage. 2010;18:476-499. 
Ampi[INVESTIGATOR_2394]™  Version 1. 3          09 November  2017  
Clinical Study Protocol: AP -003-C Confidential    
[ADDRESS_296272]  
 
SPONSOR:  
Ampio Pharmaceuticals, Inc. 
[ADDRESS_296273] 
Eng
lewood, CO [ZIP_CODE] 
[PHONE_5117] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 